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INTRODUCTION
Heart  failure  is  a  problematic  disease  in  both  developed  and
developing  countries  worldwide  with  more  than  20  million  people
affected each  year. In   developed   countries   the   prevalence  is  2%.
The   prevalence  rises  with  age, with  6-10%  of  people  affected   over
the  age  of   65  years. Women  contribute  to  50%  of  patients, this   can
be  due  to  long  life  expectancy. Overall   prevalence  is  increasing, this
can  be  contributed  in  part  by  new  advanced  therapies  for  cardiac
disorders ,  coronary  heart  disease, rheumatic  heart disease  and
arrhythmias  that  allows  a  longer  survival. Heart  failure  patients  are
classified  into  heart  failure  with  preserved  ejection  fraction  and
heart   failure  with  reduced  ejection  fraction.
Recently  our  understanding  of  heart  failure  has  evolved  to  be
more  complex involving  neuroendocrine  and  immune  system
activation. Now   we had   understood  that  not  only   the
cardiovascular  system  is  affected  here, but  peripheral  tissues  and
other  organs  also  contribute  to  symptoms  and  play  a  role  in  the
pathogenesis  and  progression  of  the  disease. Numerous  studies  show
increasing  evidence  of  role  of  uric  acid  as  a  marker  of  metabolic
and  hemodynamic  derangements in  heart  failure  patients. Uric  acid
can  also  be  used  as  a  predictor  of  survival  in  these  patients.
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AIM OF  THE  STUDY
To  estimate  the  level  of  uric  acid  in  heart  failure  patients  and
the  prognostic  importance  of  uric  acid  to  be  assessed.
OBJECTIVES  OF  THE  STUDY
To  identify  the  importance   of  uric  acid  as  a  prognostic
marker  in  heart  failure  patients.
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REVIEW  OF  LITERATURE
The  current  American  college  of  cardiology  (ACCF), American
heart association  guidelines    defines   heart   failure  as  a  complex
clinical   syndrome   that   results  from  functional  impairment  of
ventricular  filling  or ejection  of  blood , which  in  leads  to  the
cardinal   clinical   symptoms  of   dyspnea   and  fatigue  and   signs  of
heart  failure  namely  edema  and  rales.
ETIOLOGIES  OF  HEART  FAILURE
DEPRESSED EJECTION  FRACTION
Coronary  heart disease – Myocardial  infarction, Myocardial ischemia
Chronic pressure  overload –Hypertension, Obstructive  valvular  heart disease
Chronic  volume  overload – Regurgitant valvular lesions,
Intracardiac left  to  right  shunt
Extracardiac shunt
Chronic  lung  disease -Corpulmonale, Pulmonary  vascular  disorders
Nonischemic  dilated cardiomyopathy- Familial, Infiltrative  disorders
Toxin  or  drug  induced- Metabolic  disorder, Viral
Chagas disease
Disorders  of  rate  and  rhythm – Chronic bradyarrythmias
Chronic  tachyarrythmias
PRESERVED EJECTION FRACTION
Pathologic  hypertrophy –Primary( hypertrophic  cardiomyopathy )
Secondary ( Hypertension)
Aging
Restrictive cardiomyopathy (Amyloidosis, Sarcoidosis)
Storage disorders ( Hemochromatosis)
Fibrosis
Endomyocardial disorders
HIGH OUTPUT STATES
Metabolic disorders –Thyrotoxicosis
Nutritional disorders – Beriberi
Excessive  blood  flow  requirements – Systemic Arterio Venous shunting
Chronic  Anemia
Table 1. Etiologies  of  heart  failure
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Coronary  heart  disease  contributes  for  60 – 75 % of  heart
failure. Hypertension  contributes  to 75 %  of  patients, including  most
patients  with  CAD. 30 – 40 % of  patients  die  within  1  year of
diagnosis  and   60 – 70 %  die  within  5  years
PATHOPHYSIOLOGY OF  HEART  FAILURE
Repeated   attempts  have  been  made  to  unify  the  hypothesis
for  the clinical  syndrome  of   heart  failure  but  no  single   concept  has
withstood  the  test  of  time. Many  complex  model  have  been
described  by  clinician   and  investigators  to  describe  heart  failure.
Initially   it  was  viewed   that   heart  failure  is  a  disease  due  to
excessive  salt  and  water  retention that  was  caused  abnormal  renal
blood  flow (the “cardiorenal model”). Then many investigators
performed  hemodynamic  monitoring  which  lead  to development  of  “
cardiocirculatory  or  hemodynamic  model”  of  heart  failure. In  this
model,  heart  failure  was  associated  with  reduced  cardiac  output  and
peripheral  vasoconstriction. Both  the  concepts  neither  cardiorenal  nor
cardiocirculatory explained  the  progression  of  heart  failure  that
occurs  usually in  this  syndrome. Therapeutic  strategies  like  use  of
diuretics, ionotropes and intravenous  vasodilators  did  not  prevent  the
progression of  disease. Now this  has  lead  to  further  research  that  has
led  to  understanding  of  molecular  and  cellular  changes  that  are
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occurring  in heart  failure  patients  with  depressed  ejection  fraction
with  more  importance  given  for  neurohormonal  activation  and the
process of  left  ventricular  remodelling which  are  currently  considered
as  primary  determinants  of  disease progression  in  heart  failure.
Heart   failure   is  a  progressive   disorder  that  usually  starts
after  an  index event  that  either  causes   damage   to  heart  muscle,
with a resultant  loss  of number  of   functioning  myoctyes ,or
alternatively,  the  ability  of  the myocardium   to  generate   force   is
disrupted , so  that   contracting   ability   of heart   is   reduced.  The
index  event   can   be   acute   as  in  myocardial  infarction   or   can  be
gradual  or  insidious  in  onset  as  in  the  case  of  hemodynamic volume
and  pressure overloading   or  can  be  hereditary  as  in  the  case  of
cardiomyopathies. Though   the  nature  of   index  event  is   different,
the feature  that  is   common  to  all  these  events  is   a  reduction  in
the pumping  capacity  of  heart. Most  of   the  time  patient  will  remain
asymptomatic   after  the  initial  decline  in  the  pumping  capacity  of
the  heart   or  develop   symptoms   only   after   a  period  of
dysfunction. This can  be  explained  by  a number of  compensatory
mechanisms that  are  activated  in the  presence  of  cardiac  injury that
allows  patients  to  sustain  and  modulate  the  contractile function  of
the  ventricle  over  months  to  years.
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Figure 1. Progression of  heart  failure.
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Neurohormonal  mechanisms  are
1) Activation of  adrenergic  nervous  system and renin  angiotensin
system  that causes  increased  retention  of  salt  and  water, which  in
turn  maintains  cardiac  output. They  also   cause  peripheral
vasoconstriction  and  increased  contractile  function  of  heart.
Activation  of  inflammatory  mediators  is  responsible  for  cardiac
repair  and  LV remodelling.
2) Contractility of  myocardium  is  increased
3) There is  activation  of  family  of  vasodilatory  molecules   that
offsets  Peripheral vascular  vasoconstriction. The molecules  are  atrial
and  brain  natriurteric  peptides, prostaglandins and  nitric  oxide.
The  compensatory   mechanisms  are  affected  by genetic
composition, age, sex and race. This  allows  the  heart  to  modulate  left
ventricular  function   within  a  physiologic  and  homeostatic  range,  so
the functional  capacity  of  the  heart  for  variable  period  of   time  is
preserved  or  is  depressed  only  minimally. These  mechanisms
explains  why  the  patient  is  asymptomatic or  minimally symptomatic
for some  years. However  the  patient  after  a  period  of  time  becomes
symptomatic  and  this  is accompanied  by  increased  activation  of
neurohormonal, cytokine and  adrenergic  systems. This leads  to  series
of  changes  within  the  myocardium which  is  collectively  termed  as
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left  ventricular  remodeling. Increased  vascular  stiffness and  impaired
renal  function  may  additionally  contribute  in  the  development  of
heart failure  with  preserved  ejection  fraction. Currently  it is
considered  that  LV remodeling  is  sufficient  enough  to  cause  disease
progression  independent  of  neurohormonal  status  in  the  patient.
ACTIVATION  OF  SYMPATHETIC  NERVOUS  SYSTEM
Activation of  adrenergic  nervous  system  is  accompanied  by
concomitant  decrease  in  parasympathetic  tone. There  is  not  only  loss
of  inhibitory  reflexes  but  there  is  also  evidence  of  participation  of
excitatory  reflexes  in  autonomic  imbalance  that  is occurring  in
patients  with  heart  failure. Normally  there  is  inhibitory  signals  from
aortic  arch  and  carotid  sinus  baroreceptors( high pressure  receptors)
and  low  pressure  mechanoreceptors that  inhibit  sympathetic  outflow.
Whereas major  excitatory  inputs  to  sympathetic  system  are
discharges  from  nonbaroreflex  peripheral  chemoreceptors
metaboreceptors. At  rest  for  healthy  individuals  the  sympathetic
outflow  is  less and heart  rate  variability  is  high. In  patients  with
heart  failure, input  decreases  and  excitatory  signals  increase  with  the
result  of  increase in  sympathetic  nerve  traffic and  parasympathetic
nerve  traffic  is  blunted  which  results in  loss of  heart  rate  variability
and increased  peripheral  vascular  resistance. Increase  in  sympathetic
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tone  results  in  increase  levels  of  norepinephrine  in  blood. This  is
due  to combined  increase  in release  of  norepinephrine  from  nerve
endings  and   also  decreased reuptake  of  norepinephrine from  nerve
endings. The   circulating  levels  of  NE   are  two to three  times  high  in
patients  with  advanced  heart  failure  compared  to  normal  subjects. In
persons  with  heart   failure  plasma  levels  of  NE can  be  used  as  a
predictor  of  mortality. As  disease  progresses there  is  decrease  in  NE
levels  in  myocardium. This  is  explained  by  “exhaustion”
phenomenon due  to  prolonged  activation   of  cardiac  adrenergic
nerves. In addition  to this  there is  decreased  activity  of  myocardial
tyrosine  hydroxylase  which  is  the  rate  limiting  enzyme  for  synthesis
of  NE. Increased  sympathetic  stimulation  of  beta1  adrenergic
receptors  lead  to  increase  in  heart  rate and  myocardial  contractile
force  is  increased with  the  resultant  rise  in  cardiac  output.
Stimulation  of  alpha 1 adrenergic  receptors  can  elicit  positive
inotropic  effect  and  peripheral  arterial  vasoconstriction. Thus
activation  of  sympathetic  nervous  system  provides  short  term
support  but  in  long  term  this  can  become  maladaptive.
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Figure 2.  Role  of  sympathetic  nervous  system in  heart  failure.
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ACTIVATION OF  RENIN ANGIOTENSIN  SYSTEM
Activation  of  components of  RAS system  occurs
comparatively  later  in  patients  with  heart  failure. Mechanisms that
contribute  to  the  activation  of  RAS  are  renal  hypoperfusion,
decrease in  filtered  sodium  that  reaches macula densa  of  distal
tubule, sympathetic  stimulation  of  kidney  is  increased that  leads
increase  in  renin  release  from  juxtaglomerular  apparatus. Renin
cleaves  angiotensinogen  into  angiotensin I. ACE converts angiotensin I
to  angiotensin II. 90%  of  ACE  activity  is  found in tissues  and
remaining  10% is  found  in  the  heart  and  vessel  wall. There  are
renin  independent  pathways  for  the  production  of  angiotensin  II.
Angiotensin  II  can  undergo  further  proteolysis  that  produces
angiotensin  III  and angiotensin  IV that causes  vasoconstriction.
Angiotensin II  has  two  receptors AT 1 and AT2 which  are  G protein
coupled  receptors. AT1 is  predominant  in  vasculature. In  human
myocardium  the  ratio of  AT1:AT2  is 2:1. AT1  receptor  activation
leads to vasoconstriction, cell growth, aldosterone  and  catecholamine
release. AT2 receptor  activation  leads  to  vasodilation, natriuresis,
bradykinin  release  and  inhibition  of  cell  growth. Studies  have  shown
that in  failing  hearts  there  is  downregulation  of  AT1  receptors and
increased  or  unchanged  density  of  AT2  receptors. In  clinical  trials
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the  importance  of  aldosterone  has  been   demonstrated, independent
of  angiotensin  II  which  shows that  spironolactone, an aldosterone
antagonist  can  increase  the  survival  of  patients  with  systolic  heart
failure  and  survival  after  MI,  these  changes  are   found  to  be
independent  of  volume  and  electrolyte  status.
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Figure  3.  Renin  Angiotensin  system
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OXIDATIVE  STRESS
In  aroebic  metabolism  ROS( reactive  oxygen  species) are
produced  as  a normal  byproduct. The  potential  sources  include
mitochondria, NADPH oxidase and  xanthine  oxidase. ROS can  alter
the  activity  of  many  intracellular  protiens  and  signalling  pathways
which  includes  protiens  involved   in  myocardial  excitation
contraction  coupling( ion  channels), sarcoplasmic  reticulum  calcium
release  channels  and  myofilament  protiens and  pathways  related  to
myocyte  growth. When  the  production  of  ROS   is  more  so  that  it
cannot  be  buffered  by  the  antioxidant  defense  mechanisms  oxidative
stress  occurs. Mitochondrial  enzymes  manganese superoxide  dismutase
and  glutathione  peroxidase  appear  to  be  important  antioxidant
mechanisms  that  control  the  levels  of  superoxide  and  hydrogen
peroxide. In heart failure  patients, there is  evidence  of  increase  in
oxidative  stress  both  in  heart  and  systemically. This  can  be  due  to
two resaons  1) increased  production  of  ROS  that  arise  because  of
myocardial  strain, neurohormonal  stimulation, and  release  of
inflammatory  cytokines  2)reduced  levels  of  antioxidant. In   heart
failure, mitochondrial derived  excessive  ROS  can  lead  to contractile
dysfunction. In  experimental  model,s  there  is  increased  levels  of
xanthine  oxidase, an  myocardial  NADPH  oxidase in  patients  with
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heart  failure . ROS  stimulate  myocyte  hypertrophy, apoptosis and  re
expression   of  fetal  gene  programs. ROS can  alter  fibroblast
proliferation  and  collagen  synthesis  and  can  trigger  MMP activation.
ROS also  decreases  the  bioavailability  of  nitric  oxide  that  can
affect  peripheral  vasculature. This  observation  has  lead  to  suggestion,
that  therapeutics  to  reduce ROS  may  be  of  value  in  heart  failure
patients. The Oxypurinol therapy in heart  failure  has  shown  a  trend
towards  improvement only  in  subgroup  of  patients  with  highest
levels  of  uric  acid  which  is  considered  as  a  marker of  oxidative
stress. This  suggests  that  therapy  can  benefit  patients  with highest
levels  of  oxidative  stress.
NEUROHORMONAL  ALTERATIONS  IN  RENAL  FAILURE
There  is  increase  in  sodium  and  water  retention  in  heart
failure  patients  and  this  can  attributed  to  two  old  theories. They  are
“forward” faliure  and  “backward” failure  theories. Now  these
mecahnisms   have  been  supplanted  by  a  concept  of  decrease  in
“effective  arterial”  blood  volume. This  postulates  that  inspite  of
blood  volume  expansion  in  patients, the  baroreceptors  in  vascular
tree  sense  reduced  cardiac  output.  This  leads  to  activation  of  many
compensatory  mechanisms that  resembles  homeostatic  response  that
occurs in  acute  blood  loss. The  inhibitory  input  from   the
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baroreceptors  is  decreased  that  leads  to sustained  activation  of
adrenergic  nervous  and  renin  angiotensin  systems. This  causes
secondary  functional  derangemants  of  renal  physiology  that cause
increase  in  sodium  reabsorption. Other  factors  contributing are
reduction   in  renal  perfusion and  blunting  of  renal  response to
natriuretic  peptides. Decrease  in  renal  blood  flow can  be due  to  renal
sympathetic  nerve mediated  vasoconstriction. Sympathetic  stimulation
in  kidneys  can  lead to  nonosmotic  release  of  AVP( arginine
vasopressin ) from  posterior  pituitary that  contribute  to  decrease  in
free water  excretion, increased   endothelin  production  and  peripheral
vasoconstriction.
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Figure 4  Pathogenesis  of  Heart  Failure
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ARGININE  VASOPRESSIN
AVP  plays  a  central  role  in  water  clearance  and  plasma
osmolality. In normal  conditions, increase  in  plasma  osmolality  cause
release  of  AVP  that  in turn leads  to water  retention  from  proximal
duct. In  patients  with  heart  failure, inspite  of  correction  of   plasma
osmolality  there  is  increase  in AVP (i.e nonosmotic  release)  and  this
contributes  to  hyponatremia  that  occurs  in  patients  with  HF. There
are  three  types  of  receptors  for  AVP  V1a , V1b and  V2 receptors.
These  receptors  are  members  of  G  protein  coupled  receptors. V1a is
most  widespread  in  vascular  smooth  muscles, V1b in  central  nervous
system and  V2 receptors  are  found  in  epithelial  cells  of  renal
collecting  duct  and  thick  ascending  limb. Actions  mediated  by  V1a
receptors  are  platelet  aggregation, vasoconstriction  and    stimulation
of  myocyte  growth  factors.  V1b receptors  alter  ACTH  secretion  from
posterior  pituitary  and  V2 receptors  cause  water  retention  by  acting
in  distal  collecting  duct. In  animal  models, the  inhibitors  of  V1 and
V2 receptors  caused  hemodynamic  alteration  with  increased cardiac
output. The role  of  vaptans ( vasopressin  receptors  antagonists) in
heart  failure  is  under  clinical  trials.
Sympathetic  stimulation  can  cause  increase  in  renin
production, that  can  cause  sustained  RAS  activation  inspite of
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expanded  extracellular  volume. Multiple  mechanisms  by  which
angiotensin II cause  sodium  and  water  retention are  1) direct  effect
on  proximal  tubule  2)activation  of  aldosterone which   causes  increase
in  sodium  reabsorption  in  distal tubule  3) it  also  stimulates  thirst
center  in  brain, that  releases AVP and  aldosterone which  further
attributes  to  sodium  and  water  dysregulation. Many  counter
regulatory  mechanisms  are  activated  in  these  patients. They  are
1)  vasodilatory    prostaglandins    PGE2 and  PGI2 are  increased
2) natriuretic  peptides  ANP (atrial natriuretic peptide)  and  BNP (brain
natriuretic peptide)  are  increased. These  peptides  act  on  kidneys  and
peripheral  circulation and  cause  increased  excretion  of  water  and
sodium and  inhibit  release  of  renin  and  aldosterone. In heart  failure
patients  the  response  to  these  peptides  is  blunted, the  reasons
contributing  are  as  follows 1)  low  renal  perfusion  pressure  2)
relative  deficiency  of  these  peptides 3) altered  molecular forms  of
peptides 4) the peptide  receptors  are  reduced. The  resultant  effect  is
unopposed  action  of  RAS.
NATRIURETIC  PEPTIDES
The  system  contains  five  peptides  that  are  similar  in  structure.
They are ANP, BNP, CNP( C type  natriuretic peptide), urodilantin  and
dendroaspis. ANP  is  produced  from  atria and  BNP  from  cardiac
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ventricles. Both  are  produced  in  response  to increase  in  cardiac wall
tension. The  physiological  and  pathophysiological  roles  of  these  two
peptides  are almost  similar. Acute  changes  in  atrial  pressure  produce
ANP  in  short  burst. Chronic  increase  in  atrial  and  ventricular
pressure  produce  BNP. CNP  is  located  in  vasculature.  There  are  two
receptors  NPR –A (preferentially  binds ANP and BNP) and  NPR –B(
preferentially binds  CNP). Actions  mediated  by  these  receptors  are
natriuresis, vasorelaxation, renin  and  aldosterone  inhibition,  reduce
fibrosis. These  peptides  are  degraded  by  neutral  endopeptidase (NEP)
widely  expressed  in  multiple  tissues. Inhibition of  this  NEP  can
potentiate  the  actions  of  ANP  and  BNP.  Infusion of  condaxatrilat
lead  to  reduction in  levels  of  NE and plasma vasopressin  transiently.
Omapatrilat  which  inhibits  both  endopeptidase  and  ACE  was
developed  to  counteract  RAS,  also  helps  to  increase   the  levels of
natriuretic  peptides. In  many  studies  the  biological  importance  of
natriuretic  peptides  has  been  demonstrated. This  has  led  to  the
development  of  these  peptides  as  therapeutic  agents  in  heart  failure.
Recombinant  BNP is  available  and has  approved  in  US  for  use in
acute  decompensated  heart  failure.
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NEUROHORMONAL  ALTERATIONS  IN  PERIPHERAL
VASCULATURE
In HF patients  there  are  complex  interactions  between  the
autonomic  nervous  system  and  local  autoregulatory  mechanisms. This
preserves  circulation  to  brain  and  heart while  decreasing  blood  flow
to  skin, splanchnic  organs, skeletal  muscles  and  kidneys. Sympathetic
stimulation  can cause  release of  NE  and  cause  potent
vasoconstriction. Other agents  causing  vasoconstriction are angiotensin
II, ET, urotensin 2, neuropeptide Y, thromboxane  A2. This  sympathetic
stimulation  causes  arteriolar  vasoconstriction and maintains  arterial
pressure. In veins the  response  is  increase  in  venous  tone which
maintains  venous  return, ventricular  filling and  improves  cardiac
performance. The  vasoconstricting  neurohormoes  activate counter
regulatory vasodilators. They are  natriuretic  peptides, NO,
adrenomedullin, bradykinin, apelin, and  prostaglandins  PGE2 and  PGI2.
Normally there  is  continuous  release  of  NO from  endothelium  that
counteracts effects of  vasoconstrictors during  exercise. In  advanced
heart  failure,  the  release  of  NO  is  reduced and  vasodilatory  response
is  blunted. This  vasodilator  response  can  be  restored  by  giving  l-
arginine a  precursor  for  NO. The  current  neurohormonal  models  fail
to  completely  explain disease progression  in  heart failure. As  heart
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failure  progresses patients  become  unresponsive to  conventional
medical  therapy  and may  lead  withdrawal  of therapies. There  is  no
clear  explanation for  attenuation  or  loss of  effectiveness of
neurohormonal  antagonism as  disease  progresses. There is  evidence
that  progressive  LV remodeling  can  lead to  worsening heart  failure,
independent  of  neurohormonal  status  of  the  patient.
LEFT  VENTRICULAR  REMODELING
Studies  have  shown that  progressive  LV remodeling  can  cause
a  decrease  in LV performance  and  poor  prognosis. There  is  change
in  the  biology  of  myocyte, volume  of  myocyte and also changes  in
the  nonmyocyte  component  of  myocardium.
Alterations  in  Myocyte  Biology
Excitation contraction coupling
Myosin  heavy  chain  fetal  gene expression
Beta adrenergic  desensitization
Hypertrophy
Cytoskeletal proteins
Myocardial  changes
Myocyte  loss- necrosis, apoptosis,
autophagy
Alterations  in  extracellular  matrix
Matrix  degeneration
Myocardial fibrosis
Alterations  in  left ventricular chamber
geometry
LV dilatation
Increased  LV  sphericity
LV wall  thinning
Mitral valve  incompetence
Table 2  Alterations  in the  cells  of  left  ventricle in  heart  failure
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ALTERATIONS   IN   CARDIAC   MYOCYTE   BIOLOGY
In hemodynamic  overload  there  are  two  basic  patterns  by
which  cardiac  hypertrophy  occurs.  They  are  as  follows 1) concentric
hypertrophy   or  pressure  overload  hypertrophy, in this  pattern  there  is
systolic  wall  stress  that   leads  to addition  of  sarcomeres  in  parallel
so  myocyte  cross sectional  area  is  increased. Aortic  stenosis  and
hypertension  cause  this  type  of  hypertrophy,  2) eccentric  hypertrophy
or  volume  overload  hypertrophy, in this  pattern  there  is diastolic
wall  stress which  leads  to  addition  of  sarcomeres  in  series  so
myocyte  length  is  increased.
In  cardiac  myocyte  there  is  reactivation  of  fetal  genes  called
as  “ fetal  gene  program” .this  can   contribute  to  contractile
dysfunction that  occurs  in  failing  myocyte. The  stimuli  for  this  can
be  mechanical  strain  in  a  myocyte, neurohormones  like  NE,
angiotensin  II, inflammatory  cytokines  (TNF, interleukin  6 ), growth
factors  and   reactive  oxygen species  (superoxide, NO). These  stimuli
can  act   both  locally  and  systemically causing these  changes. In  early
stages  there  is  increase  in  number  of  myofibrils and  mitochondria,
but  cellular  organisation  is  preserved. In  longstanding  hypertrophy
there is  disruption  of  cellular  organisation, which  is  accompanied  by
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displacement of   myofibrils.   In  later  stages  it  is  accompanied  by
myocytolysis  that  cause  dilation  and  tortuosity  of  t  tubules.
Figure 5 Two  types of  hypertrophy in  LV  remodeling
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Alteration  in  excitation  contraction  coupling
Studies  have  shown  that  in  end  stage  heart  failure, there  is
abnormal  prolonged  action  potential, depressed  force  and  impaired
relaxation. The delivery  of  calcium  to  the  contractile  apparatus  is
depressed  which causes  slowed  contraction  and  relaxation.
Abnormalities  in  contractile  and  regulatory  protiens
The   activity  of  myofibrillar  ATPase, actomyosin  ATPase  or
myosin  ATPase  is  reduced in  patients  with  heart  failure. In  normal
myocardium  alpha  myosin  heavy  chain  which  normally  constitutes
33%,but  this  is  reduced  in  heart  failure  patients. In  patients
recieving  beta  blockers, there  is  increase  in  alpha  myosin  heavy
chain and  this  can improve  LV  function. Additional  modification  in
the  contractile  protiens  that  contributes  to  contractile  dysfunction  is
myocytolysis. In  advanced  LV dysfunction  the volume  of   myofibrils
is  significantly  reduced, this  can  lead  to  cardiac  decompensation. In
normal  myocardium  troponin T  is  expressed  as  a  single  isoform  but
in  patients  with  end  stage  heart  failure  there  is  increased  expression
of  fetal  isoforms  cTnT1  and  cTnT4, that  can  lead  to  decrease  in
maximal  active  tension.
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Abnormalities  in  cytoskeleton  protein
The  cytoskeletal  protiens  in  cardiac  myocytes  are  catin,
desmin, titin, alpha  and  beta  tubulin. In  experimental  studies  the role
of  cytoskeletal  protiens  in  cardiac  failure  has  been  implicated. In
patients  with  dilated  cardiomyopathy, there  is  downregulation of  titin,
whereas  other  protiens  like  viculin and dystrophin  are  upregulated.
This  loss of   integrity  in  cytoskeletal  structures  can  lead  to
contractile  dysfunction  at  the  myocyte  level.
Beta  adrenergic  desensitization
In  heart  failure  patients  it  has  been  demonstrated  that  there  is
a reduction  in  beta  adrenergic  receptor  density, contractile  response
to  beta  agonists and  isoproterenol  mediated  adenylyl  cyclase
stimulation. This  reduction in  receptors  involves   primarily  beta1 -
receptors and mRNA  whereas  beta2- receptors and mRNA  are
unchanged. The  overexpression  of  beta  adrenergic  receptor  kinase  1
(G  protein  coupled  receptor) can  lead  to  reduction  in  receptor
recycling  and  reactivation  but  rather  leads  to  receptor  degradation.
Thus  this  can  contribute  to  desensitization  of  both  beat  adrenergic
receptors. This  desensitization  can  be  both  beneficial  or  deleterious.
Desensitization  can  reduce  LV contractility  that  can  be  deleterious.
The  beneficial  effect is  it  can  reduce  the  energy  expenditure  in
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already  energy  starved  myocardium  and  can  protect  the  myocyte
from  sustained  adrenergic  stimulation.
Alterations  in  myocardium
This  can  be  broadly  categorised  into  changes  that  occur  in
cardiac  myocyte  volume   and composition  of  extracellular  matrix.
There  is  increasing  evidence  that  suggests progressive  loss of
myocytes,  that  may  be  due  to  necrosis, apoptosis  or  autophagy. This
contributes  to  LV  remodelling  and progressive  cardiac  dysfunction.
Second  important  thing   is   changes  occuring   in  ECM  composition.
ECM consists  of  basement  membrane, fibrillar  collagen  network
(fibrillar  collagen  type  1  and  3  in  the  ratio  of  1.9: 1) that  surrounds
the myocyte and signaling molecules. In  cardiac  remodelling  there  is
change  in   fibrillar  collagen  synthesis and  degradation, the  degree  of
collagen  cross linking and  loss of  collagen  struts  that  connects  each
cardiac  myocyte.  In RALES  trial  it  was  found  that  the  markers  of
collagen  turnover  are  decreased  in patients  treated  with
spironolactone  compared  to  placebo  group  which  established  the  fact
that  aldosterone  may  have  role  in  ECM  synthesis.
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Cardiac  fibroblasts  and  mast  cell
The  cardiac  fibroblasts  comprise  of  more  than  90%  of
nonmyocyte  cells  in  heart  and  this  is  responsible  for  secretion  of
major  ECM components  such  as  collagens,  laminin, fibronectin. A
subset   of  fibroblast  undergo  phenotypic  conversion  in  response  to
mechanical  stress or  neurohormonal  activation  that  leads  to  increase
in  expression  of  alpha smooth  muscle actin and  secretory  activity.
When  tissue  injury  occurs  these  myofibroblats  migrate  to those
areas and  play  a  important  role  in  final  scar  formation. Secondly
myocardial  mast  cells  that  are  found  surrounding  blood  vessels  and
myocytes  are  capable  of  releasing   profibrotic  cytokines  and  growth
factors that  causes ECM remodeling.
In  failing  heart  there  is  increase  in  collagen  content  of  heart
(the  ratio  of   type  1 to  3  collagen  is  altered), loss of  cross  linking
of  collagen and  connectivity  to  each  myocyte  which  would  lead  to
alterations  in  LV  function  by  altering  the  structure. The
accumulation of  collagen can  be “ reactive” that  can  surround  vessels
(perivascular  fibrosis) or  in  interstitial  space (interstitial  fibrosis), and
essentially  does  not  require  myocyte  death. Alternatively, collagen
deposition  can  be  due  to  microscopic  (replacement  fibrosis) that
occurs  in  response  to  myocyte  cell  necrosis. This  replacement
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fibrosis  is  essential  to  replace  the  lost  volume  of  parenchyma and
is  critical to  preserve  the  structural  integrity  of  heart. The  increase
in  fibrous  tissue  can  lead  to  myocardial  stiffness which  would  affect
myocardial  shortening  for  a  given  afterload. In  addition  this  fibrosis
can  form a  substrate  for  atrial  and  ventricular  arrhythmias and  can
lead  to  sudden  death. Factors  contributing  to  increase  in  fibroblasts
are  angiotensin, aldosterone ,cytokines and TGF-beta. ACE inhibitors,
beta  blockers and aldosterone  receptor  antagonists  have  proved  to
reduce  myocardial  fibrosis  in experimental  models. It  has  been
discovered  that  a  family  of  collagenolytic  enzymes collectively
called  as  matrix  metalloprotienases  are  activated  in  failing
myocardium. Disruption of  ECM  can  lead  to  LV wall  thinning  and
dilation, dysynchronous  contraction  that  results   in  LV  dysfunction. It
is  found that  TNF, cytokines and  growth  factors  are  capable  of
activating  MMPs. The  process  of  ECM  remodeling is  more  complex
that  glycoprotiens  called “tissue  inhibitors of  matrix
metalloprotienases”  also  control  the  degradation  of  matrix  by
binding  and  inhibiting  the  MMPs  and  prevent  matrix collagen
degradation. TIMP  consists of  four  distinct  members  TIMP -1,2,3
and4.
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Alterations  of  left  ventricular  structure
It  was  observed  that  the  remodelled  ventricle  was  not  only
larger  but  also  spherical  in  shape  rather  than  elliptical. This
increases the  meridonial wall  stress of  left  ventricle that  creates  a
energy  burden  for  the  failing  heart. Thus  LV dilatation  itself  will
increase the  energy  expenditure  of  failing  heart. There  is  increase  in
LV  end diastolic  volume  and  LV wall  thinning  also  occurs  as
ventricle  remodels. This causes  a  afterload  mismatch  and  a  decrease
in  forward  cardiac  output. Increase  in  wall  stress  can  lead  to  the
following  effects  1) sustained  expression of  stretch  activated  genes
and hypertrophic  signalling  pathways, 2) episodic  hypoperfusion  of
subendocardium  that  worsens  LV  function 3) activation  of  genes  that
can  increase  free  radical  production  thereby  increasing  oxidative
stress 4) papillary  muscles  are  pulled  apart leading  to mitral  valve
incompetence  and  functional  mitral  regurgitation further  increasing
volume  of  the  ventricle. All the  above  mentioned  effects  can  lead  to
worsening  of  LV  function   independent  of  neurohormonal  status in  a
failing  heart.
Inflammatory  mediators
Usually  proinflammatory  cytokines  are  produced  by  the
immune  system, but  it  is  found  that  they  can  be  produced  locally  in
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the  myocardium  by  the  myocytes  in  direct  response  to injury.
Primary  role  of  these  molecules  is  to  repair  the  injured part, when
they  are  produced  for  a  prolonged  period  of  time  this  itself  can  be
deleterious and  cause   alteration in  cardiac  myocytes, nonmyocytes and
extracellular  matrix. In  experimental  models  it  was  found  that  there
is  cross  talk  between  these  inflammatory  mediators  and  RAS.
Angiotensin  II  can  upregulate  TNF and  these  inflammatory
mediators  can lead  to  upregulation  of  RAS  by  increasing  myocardial
ACE and chymase. In  heart  failure  patients  there  is  increase  in  levels
of  TNF and  interleukin-6.  Anti-inflammatory  markers  like  IL 10 are
reduced  in  patients  with  heart  failure. This  shows  that  this
imbalance  between  pro  inflammatory   and  anti inflammatory
mediators  may  cause  progression   in  heart  failure.
Effect  of  inflammatory  mediators  on  left  ventricular remodelling
Alterations in biology of myocyte
Myocyte Hypertrophy
Fetal gene expression
negative ionotropic effects
increased oxidative stress
Alterations in the biology of nonmyocytes
Conversion of fibroblasts to myofiroblasts
Upregulation of AT1 receptors on fibroblasts
Increased matrix metalloproteinase
secretion by fibroblasts
Alteration in extracelluar matrix
Degradationof matrix
Myocardial fibrosis
Progressive myocyte loss
Necrosis
Apoptosis
Table 3. Alterations  in  myocyte  in LV  remodeling
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Figure 6.Molecular  changes  in  LV  remodeling
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Myocardial  recovery ( reversibility  of  LV  remodeling )
This  process  of  recovery  of  myocardium  which  occurs  at
various  levels  as  at  the  molecular, tissue, cellular  and  organ  levels
has  been referred  as  “reverse  remodeling”.  From  clinical  studies  it
was  found   that   with  current  pharmacological and  device  support this
recovery  has  been  possible  to  some  extent  but  there are  limits  to
the  amount  of  recovery. Patients  on  beta  blockers  who  had  an
improvement  in  ejection  fraction had  an  increase in  SREC2A  mRNA
and  alpha- myosin  heavy  chain   mRNA  and  a  reduction  in  beta-
myosin  heavy chain mRNA  that  explains the  improvement  in  LV
function   after   beta   blockers   treatment  by  alteration  in  gene
expression. Similar  results  have  been  observed  after  treatment  with
ACE  inhibitors  or  cardiac  support  devices. In  patients  with  dilated
cardiomyopathy  who  were   treated  with  LVADs a pharmacological
regimen  that  consists  of  ACE  inhibitor, an  angiotensin  receptor
blocker, an  aldosterone  antagonist, and  a beta  blocker  followed  by
treatment  with  beta2 receptor  agonist  (clenbuterol)  caused  sufficient
myocardial  recovery  and  an  improvement  in  quality  of   life  and
reduced  the  incidence  of   recurrent  heart  failure  over  next  1 to 4
years.
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HEART    FAILURE   WITH   NORMAL  EJECTION FRACTION
In  the  last  two  decades, the  possibility  that  large  number  of
patients  with  heart failure  might  have  normal  ejection  fraction  was
not  considered.  Recent  studies  have  shown  the  prevalence  of  heart
failure  with  normal  ejection  fraction  has  increased over  time  over
the  past  15  years   and  this  has  lead  to its  widespread  recognition.
Nearly  13  studies  have  documented the  prevalence  is  50  to 55 %.
Importantly  the  prevalence  varies  with  age  and  gender. It  was  found
that  the  prevalence  increases with  age and  it  is   similar  in  both men
and women. Recent  studies  have  suggested  that   the  mortality  is
similar  in  both  groups  of  heart  failure. The  difference  in  survival
are  minimal   between  two  forms  of  heart  failure. The
pathophysiological   mechanism   are   similar   compared   to   heart
failure  with   reduced   ejection   fraction. This   includes   decreased
exercise  capacity, compensatory   neuroendocrine  mechanism  and
impaired  quality  of  life. This  is  present  inspite  of  normal   ejection
fraction   and   LV   volume   and   increased   LV   mass   to   volume
ratio.
PATHOPHYSIOLOGY
To  understand  the  pathophysiology  of  heart  failure  with
normal  ejection fraction, it  is  mandatory  to  understand   LV   systolic
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and  diastolic  function  and   how   LV  function  is   altered  by  volume
status  that  determines  preload  and  arterial  system  which   affect
afterload.  It  has  long  been  hypothesized  that   abnormal  diastolic
function  is  the  primary factor  causing   hemodynamic   alterations  and
symptoms  in patients  with  heart  failure  with   normal  ejection
fraction. In the recent past, multiple studies  has   been   attempted   to
prove   this  by  studying  diastolic  function  in patients and   in  control
populations. It  is  noteworthy  to  know  how LV structure  and  function
is  different  between  persons  with  HFnlEF  and  people  with
cardiovascular  disease   but   no  heart  failure.
Demographic   features   and   comorbid   condition.
These   patients  are  usually  more  than  65   years  and  more
common in women  contributing  60-70%   of total  patients. 60-80 %
have  history  of  hypertension, 30-50%  have  obesity, 30-50% have
diabetes  and   20-40 %  atrial  fibrillation. The prevalence  of  renal
disease  is  also  high  in  this  group  of  patients.
Aging
It has been found that diastolic function declines with age. This can
be  attributed  to  declining  LV  relaxation  with  age  in  both  men  and
women. Also vascular, LV systolic  and  LV diastolic  stiffness  increases
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with  age.  This  can  contribute  to  effort  intolerance  noted  in  these
group  of  patients. Aging  can  also  cause  changes  in  cardiac  structure
and  changes  in  function at the cellular level  like decreased beta
adrenergic  response, alterations in  excitation  and  contraction  coupling,
and  calcium  handling  proteins contributing  to  diastolic  dysfunction
that  occurs  with  normal  aging.
Gender
The  reason  for  female  predominance  is  not  clear  but  vascular,
LV systolic and  LV diastolic  stiffness  is  more  common  in  women.
This can be attributed  by  the  unique  functional  changes  that  occur  in
women  with  HFnlEF.
Hypertension
Most  commonly  hypertension is  associated  with  HFnlEF.
When  blood  pressure  is  increased  for  longer  duration  it  can  act  as
a  stimulus  for  changing  structure  and  function. The  changes
occurring  in  hypertensive  heart  disease includes  LV hypertrophy,
increased vascular stiffness and ventricular  stiffness, impaired
relaxation, increased diastolic  stiffness, contributing  to  the
pathogenesis  of  HFnlEF. When  ischemia  is  present  in hypertensive
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heart  disease patients  it  can  exaggerate  symptoms due to  increase in
LV filling  pressure.
Coronary  heart  disease
It  is  uncertain  how  ischemia  contributes  to  the
pathophysiological  mechanisms  of  HFnlEF. In  women  there is
emerging  evidence  for occurrence of  unique  functional  changes
(diffuse disease, more  endothelial  dysfunction)  in  heart.
Atrial  fibrillation
This  is  well recognised  precipitating  factor  for  acute
decompensation  of  heart  failure. In  diastolic  dysfunction  atrial
fibrillation  can  cause  acute  decompensation  whereas  diastolic
dysfunction  itself  is  a  risk  factor  for  atrial  fibrillation. Thus in
HFnlEF  atrial fibrillation  and  diastolic  dysfunction  all  are  interrelated
and  share  a  common  mechanism.
Obesity
Obesity  is a known  risk  factor  for  heart  failure. This is  because
the  prevalence  of  diastolic  dysfunction  is  increased  in  obese
patients. The  mechanism  behind  this  is  probably  chronic
inflammation  mediated  by  the  peptides and  non peptide  mediators
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released from  adipose  tissue. Additionally obesity  in turn is  risk  factor
for  diabetes, coronary  heart  disease, atrial  fibrillation all of  which  are
linked  to  HFnlEF.
Diabetes  mellitus
The  prevalence  of  diabetes  is  almost  similar  in  patients  with
heart  failure  with  reduced  and  preserved  ejection  fraction. Multiple
direct effects  of  diabetes  on  myocardial  structure  has  been  described
recently. This  includes  myocyte  hypertrophy, increased extracellular
matrix (fibrosis), and  intramyocardial  microangiopathy. Functional
changes  are  endothelial  dependent  and  independent  microvacular
dysfunction, impaired  relaxation, and  increased passive  diastolic
stiffness  and  contractile  dysfunction. Mechanisms  contributing  are  as
follows      1) metabolic  alterations  2) activation of  proinflammatory
profibrotic  mediators      3) cardiac  autonomic  neuropathy  and  4)
increased advanced  glycation end  products which  promote  increased
collagen  accumulation  and  increased  collagen  stiffness.
Renal  dysfunction
Studies  have  established  no  difference  in   the  severity  of  renal
dysfunction  in  patients  with  reduced  and  preserved  ejection  fraction.
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Evaluation  of renal  arteries  is  important  in  patients  presenting  with
triad  of  hypertension, renal  dysfunction, and  HFnlEF.
Other  rarer  causes are  hypertrophic  cardiomyopathy, infiltrative
cradiomyopathies, valvular  diseases, and  constrictive pericarditis.
Idiopathic  restrictive  cardiomyopathy  with  a  positive  family  history
can  be  a  distinct  cause  of  HFnlEF. Radiation  heart  disease  is  a
distinct  entity  in  patients  with  malingnancy  treated  previously  with
radiation.
URIC ACID
Uric  acid  is  produced  in   final  steps  of  metabolism of  purine
nucleotides  by  xanthine  oxidase  in  a  bivalent   process  that   resulted
in  the  formation  of  superoxide ion. Final elimination is by renal and
GIT. Up-regulation  of  xanthine  oxidase  activity  may  produce
increase  in  serum  uric  acid level and oxidative  stress, endothelial
dysfunction and  left  ventricular  dysfunction. This has been  linked to
the pathogenesis of heart failure.
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Renal (2/3),Gastrointestinal (1/3)
Figure 7  Metabolism  of  purines
The  role  of  uric  acid  as  a cause of  heart  failure  remains
controversial. Till date  a  clear  pathophysiological  link  between  uric
acid  and  heart  failure  complications  and   mortality  is  yet  to  be
confirmed. Uric  acid  is  related  to  many  risk  factors  for  heart  failure
like  dyslipidemia   and  hypertension, indicating  that  uric acid  might
in-turn  be  a  marker  of  increased   risk. Several  studies  in  the   past
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have  estimated  whether  uric  acid  is  an  independent  risk  factor for
heart  failure  but  the  results  were controversial  and  erratic.
Further  evidence of   use  of  xanthine  oxidase  inhibitors  to
reduce  serum  uric  acid  levels showed  improvement  in  cardiac
function,  endothelial  activity  and  EF  which  lead  to better  results  in
heart  failure. It  has  been  constantly  reported  that  heart  failure
patients  have  increased  uric  acid  levels  in  blood. It  has been  found
that  serum  uric  acid  levels  can  provide  important  prognostic
information  either  alone  or   in  combination  with  other  risk  factors
of  heart  failure. Many  studies  have  revealed   that  increase  in  uric
acid  levels can increase  relative  risk  of  mortality  in  patients  with
heart  failure  that  was  independent  of  other  risk  factors. This
relationship was  especially  strong  in  patients  who  presented  with
acute  HF  exacerbations The  role  of  xanthine oxidase   in  the
pathophysiology  of  heart  failure  is  being  studied.
Further  in  the  past, uric  acid  has  been   related  to several
known  risk  factors  of  heart  failure, especially  hypertension. There are
multiple  reports  suggesting that  hyperuricemia has  an  increase  in
risk  of  developing  hypertension that  is  not  related  to  other  risk
factors. This  relationship  is  more  consistent  in  adolescents  with
primary  hypertension, whereas  the  association  in  older individuals
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and  in  persons  with  established  hypertension  is  varying. Numerous
studies  have  reported  hyperuricemia  in  hypertensive  patients  who
are  at  risk  of  developing  heart  failure, although  some  studies  have
reported  lower  incidences. In  many  multiparametric  heart  failure
models, such as  Seattle   Heart  Failure  Model  and  Study  of  the
effects  of  Nebivolol  Intervention  on  outcomes  and  Rehospitilization
in  Seniors  With  Heart  Failure (SENIORS) Model1, hyperuricemia  has
been  acknowledged  as  an  effective  predictor  of  prognosis.
Uric  acid  and   xanthine  oxidase  in  heart  failure  pathophysiology
Recent  experimental  trials  have  suggested  important  role  of
xanthine  oxidase  and  uric  acid  in  the  pathophysiology  of
progression of  heart  failure. Xanthine  oxidase  activity  produces  a
molecule  of  superoxide  for  each  unit   of  uric  acid   produced,  the
upregulation  of  this  pathway  may  cause  increase in  oxidative  stress
which  plays  key  role  in  the  pathogenesis of  heart  failure. In  both
animal  and  human  experimental  models with  heart  failure  increase
in  xanthine  oxidase  activity  has  been  noted. Other  than  oxidative
stress  other  factors  contributing to  pathophysiology of heart  failure
includes vascular  dysfunction, mechanoenergetic  uncoupling,  and
depressed  myocardial  function. In  multiple  animal  studies  it  has
been  documented that  hyperuricemia  causes downregulation  of  nitric
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oxide  activity  in  endothelial  smooth  muscle  cells  by  increasing
reactive  oxygen  species. This  leads  to  decrease  in  available  NO  and
loss  of  NO  dependent   vasodilation  finally  causing  endothelial
dysfunction. There are  some  points  favouring  the  role  of  uric  acid  as
a  antioxidant  which  can  reduce  effect  of  ROS,  but  there  is
evidence  that   hyperuricemia  by   itself  reduce  the  amount  of  NO
synthase  and  impairs  the  vasodilatation  caused by  NO.
Accumulating  evidence  suggests  that  UA, beside  from  being  a
appreciated  prognostic  marker, possesses  certain  toxic  effects  that
may  contribute  to  HF  pathogenesis  beyond  a   consideration  of
increase  in    XO  activity. In experimental studies  done  in  animal, uric
acid  was  found  to  be  a  potent  stimulator  of  intrarenal  smooth
muscle  cell  proliferation in  vessels, that  may  lead  to  substantial
hemodynamic  changes  in a  failing  heart.
Xanthine  Oxidase  inhibition  and   outcomes in  HF
In  the  recent  past, many  clinical  trials   have  suggested  that
XO  inhibition  can  lead  to favourable  hemodynamic  changes  and
better  clinical  outcomes in  patients  with  congestive heart  failure. It
was found  that  in  a  subgroup  of  HF  patients  with  hyperuricemia,
lowering  serum  uric  acid  had  beneficial  effects  like  endothelial
reactivity, improved myocardial  function, and  increase in  ejection
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fraction. Initially  studies  revealed  that  uric acid can  affect   nitric
oxide  mediated  vasodilatation. When  treated  with  allopurinol  these
patients  had  an  increase  in  peak  blood  flow  in  peripheries  by
reducing  levels  of  uric  acid  and  allantoin  in  circulation, a  marker  of
free  radical  generation. In  another  study, treatment  with  allopurinol
also  improved  endothelial  dependent  vasodilatation  by  reducing
levels  of  maldondialdehyde,  another  marker  of  oxidative  stress.
In  both studies, the  projected  mechanism  was  by  an  increase
in  the  bioavailability  of  NO  that was  derived  from  endothelium,
seemingly  by  blocking  the  production  of reactive  oxygen  species
produced   by  XO   pathway,  as  proved  by  substantial  reduction  in
markers  for  oxidative  stress. This  hypothesis  has  been  reinforced  by
several  studies  in  recent  past. In  two randomized, placebo  controlled,
double  blind,  cross  over  studies  by  George  and  collegues2 that
compared  the  effect of  allopurinol  and  placebo  in  the  first  study
and  probenecid  and  placebo  in   the  second  study, the  uricosuric
agent  probenecid  showed  no  changes  in  endothelial  function  for
same  levels  of   decrease  in   uric  acid  in  serum. Recently  a
preliminary, placebo  controlled,  double  blind  cross over  study  by
ogino  and  associates3 revealed  UA  lowering  with  the  uricosuric
agents  benzbromarone  in  14  patients   with  congestive  heart  failure
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and  hyperuricemia did  not  improve  hemodynamic  impairment
although  uric   acid  levels  reduced  significantly. These  findings  show
that  upregulted  XO  pathway  rather  than   uric  acid  levels  is  involved
in   HF  pathogenesis   and  that  the improvement  with  allopurinol  may
be  due  to  its  ability  to decrease   oxidative  stress  and  not  serum  uric
acid  levels.
From  the  functional  perspective,  Xanthine  oxidase  inhibition
may  have  better  outcomes  in  cardiac  function. A  study  by Cappola
et al4 in  patients  with  dilated  cardiomyopathy,  treatment  with
intracoronary  allopurinol   had  led  to  a  decrease  in  myocardial
oxygen  utilization  with  no  parallel  reduction  in  stroke  work, causing
a considerable  improvement  in   efficiency  of  myocardial  function.
Recently   La  Plata Study, a  randomized, double –blind, placebo
controlled   study  in  60  patients  with  NYHA  II  or  III congestive
heart  failure, exposed   the   capability  of  Oxypurinol  to  improve  left
ventricular   EF   in  patients  with  ejection  fraction < 40%. By
potentially  reversing  the  energy  consumption of  myocardium  and  by
increasing  the  cardiac  output  of  the  failing  heart, pharmacologically
inhibiting  xanthine  oxidase   may  provide   new   novel  therapeutic
options in  the  treatment  of   congestive  heart  failure.
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To  the  extent  that  XO  inhibition  may  lead  to  improvement  in
clinical  outcomes, the  Efficacy  and  Safety  Study  of  Oxypurinol
Added  to  Standard  Therapy   in  patients  with  NYHA  Class  III  and
IV  CHF  study  randomized  405  patients  with  moderate  to  severe
congestive  heart  failure   due  to  systolic  dysfunction, treated with
either  oxypurinol  or  placebo5. Using  a  composite  end  point  of  HF
morbidity, mortality,  and  quality   of  life,  Oxypurinol  did  not  give
clinical  improvement  in  unselected  patients at  24  weeks. However
in  past  hoc  analysis, it  was  revealed  that  patients  with  elevated
levels  of  UA   might  represent  a  responsive  group, as  there  was  a
trend  towards   benefit   in   patients  who  received  Oxypurinol  in  this
subgroup. This improvement  related  well  with  clinical  outcomes  in
patients  with hyperuricemia  group. Together  this  suggests   that  UA
can  serve  as  a  valuable  biomarker  to  target  Xanthine  Oxidase
inhibition  for  selected   patients  with  HF,  and  this   also  correlates
well  with  the  degree  of  serum  uric acid  reduction.
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MATERIALS  AND  METHODS
SOURCE  OF  STUDY
Data  consists  of  primary  data  collected  by  the  principal
investigator   directly  from  the  patients  who  were   admitted  in
Government Coimbatore  Medical College  and  Hospital
DESIGN  OF  THE  STUDY
 Prospective  study
PERIOD  OF  STUDY
 One  year  July 2016- June 2017
SAMPLE  SIZE
 100   patients
INCLUSION  CRITERIA
 Patients  above  the  age  of  18  years  with  ejection  fraction  less
than  55%.
EXCLUSION  CRITERIA
 Patients  with  gout
 Patients  with  acute  and  chronic  renal  failure
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 Patients  with  prior  history  of  malignancy
 Patients  not  capable  of  giving  consent ( psychiatric
patient)
 Patients  not  willing  to  participate  in  the  study
 Pregnant  and  lactating  women
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METHODOLOGY
The  study  will be  undertaken  on  the  patients  attending
medicine  inpatient  department  and  admitted  in  Coimbatore  medical
college  and  hospital,  Coimbatore  during  the  study  period  July  2016-
June 2017. A total  of  100  patients  with  heart  failure  are  included  in
the  study  based  on   the  inclusion  and  the  exclusion  criteria.
The  list  of  patients  enrolled  in  the  study  is  appended along
with  the  dissertation. The  study  excludes  minors, pregnant  women,
mentally  ill  and  non  volunteering  patients.
The  study  is  proposed  to  be  conducted  after  obtaining
informed  consent  from  the  patients.  The   duration of  study  is  one
year  July 2016- June  2017. A  detailed  history, clinical  examination
and  ECHO  evaluation  was  done  for  all  patients.
1) Blood  sample  was  collected  from  patients  and  analysed  by
standard  methods  for  blood  sugar, urea  and creatinine.
2) Serum  uric  acid  to  be  analysed  by  automatic  chemical
analyser.
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3) Significant  differences between serum  uric  acid  in  different
subgroups  to be  observed  over  a  period  of  one  year  and  role
of  uric  acid  as  a  prognostic  marker  to  be  evaluated.
INVESTIGATIONS
 Serum  uric  acid
 Blood  urea
 Serum  creatinine
 Blood  sugar
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OBSERVATIONS  AND  RESULTS
AGE DISTRIBUTION
AGE (IN YEARS) NO OF PATIENTS PERCENTAGE
< 40 12 12%
41-50 31 31%
51-60 24 24%
61-70 22 22%
> 70 11 11%
Table  4.  Age  distribution
Chart  1. Age  distribution
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SEX DISTRIBUTION
70% percent  of  study  population  were composed  of  males and  30 %
were  females
SEX NO OF PATIENTS PERCENTAGE
MALE 70 70%
FEMALE 30 30%
Table 5. Sex  distribution
Chart  2.  Sex  distribution
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DISTRIBUTION  OF  SMOKING
Nearly  half  of  the  study  population  were  smokers  54%  were
smokers
SMOKING NO OF PATIENTS PERCENTAGE
PRESENT 54 54%
ABSENT 46 46%
Table  6 : Distribution of  smokers and  non  smokers.
Chart   3. Distribution  of  smokers and  non  smokers
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DISTRIBUTION  OF  CREPITATIONS  AND  PEDAL  EDEMA
CREPITATION & PE NO OF PATIENTS PERCENTAGE
PRESENT 42 42%
ABSENT 58 58%
Table  7. Distribution  of  patients  with  crepitations and  pedal
edema
Chart   4 . Distribution  of  patients  with  crepitations  and  pedal
edema
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DISTRIBUTION  OF  DIABETES
DIABETES MELLITUS NO OF PATIENTS PERCENTAGE
PRESENT 38 38%
ABSENT 62 62%
Table 8.  Distribution  of  diabetes  mellitus
Chart 5  Distribution  of  diabetes mellitus
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HYPERTENSION  DISTRIBUTION
HYPERTENSION NO OF PATIENTS PERCENTAGE
PRESENT 39 39%
ABSENT 61 61%
Table  9. Distribution  of  hypertension
Chart 6. Distribution  of  hypertension
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NYHA CLASS
Distribution  of  patients based on  NYHA  class  in  the  study  group
NYHA CLASS NO OF PATIENTS PERCENTAGE
I 7 7%
II 30 30%
III 37 37%
IV 26 26%
Table  10.  Distribution  of   patients  based  on NYHA class
Chart  7.  Distribution  of  patients  based on  NYHA class
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EJECTION  FRACTION
38%  of  patients  had  an  ejection  fraction  that  is  < 40%
EJECTION FRACTION NO OF PATIENTS PERCENTAGE
< 40 % 38 38%
> 40 % 62 62%
Table 11. Grouping  based on  ejection  fraction
Chart  8. Grouping  based on  ejection  fraction
EJECTION FRACTION
< 40 % > 40 %
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URIC  ACID
38 %  of  patients  had  high  uric   acid  levels and  62  had   less  than
6.8 mg/dl.
SERUM URIC ACID NO OF PATIENTS PERCENTAGE
HIGH (>6.8) 38 38%
ABSENT(<6.8) 62 62%
Table  12  Distribution  based  on  uric  acid
Chart  9: Distribution  based on  uric  acid
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DURATION  OF  DISEASE
DURATION OF DISEASE NO OF PATIENTS PERCENTAGE
< 5 YRS 91 91%
> 5 YRS 9 9%
Table  13. Grouping  based  on duration  of  disease
Chart  10  Grouping  based  on  duration of  disease
This  shows  that  only   9 %  of  patients  had  disease  for  more  than  5
years  duration.
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NUMBER  OF  ADMISSIONS
NO OF ADMISSIONS NO OF PATIENTS PERCENTAGE
ONE 55 55%
TWO 27 27%
THREE 15 15%
FOUR 3 3%
Table  14. Distribution based  on  number  of  admissions
Chart  11.  Grouping  based  on  number  of  admissions
This  shows  that  55%  of  study  had  admission  only  once  during  the
study  period.
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PROGNOSIS  IN  STUDY
PROGNOSIS NO OF PATIENTS PERCENTAGE
DEATH 16 16%
ALIVE 84 84%
Table  15. Mortality  in  study
Chart 12. Mortality  in  study
This  shows  that  16 %  of  patients  died  during  the  study  period
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SERUM  URIC  ACID  AND AGE
This  table  shows  the  correlation  of   levels of   uric  acid  and
age. There  is  a  significant  correlation  between  increasing  age  and
uric  acid.
SERUM URIC ACID
AGE( IN YEARS) HIGH LOW
<40 2 10
41-50 15 16
51-60 13 11
61-70 18 4
>70 9 2
P VALUE - 0.002
SIGNIFICANT
KRUSKAL WALLIS TEST
Table 16. Correlation  between  age  and  uric  acid.
Chart  13. Correlation  between  age  and  uric  acid
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MEAN  URIC  ACID AND  AGE
SERUM URIC ACID
AGE (IN YEARS) MEAN S.D
<40 5.8 1.1
41-50 8.02 1.3
51-60 7.1 1.5
61-70 7.5 1.8
>70 8 1.3
P VALUE - 0.008
SIGNIFICANT
ANOVA
Table 17.  Mean  uric  acid  versus  age
Chart  14.  Mean  uric  acid  versus  age.
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URIC  ACID  AND  GENDER
This  table  shows  there  is no  significant  correlation  between   serum
uric  acid  and  sex of  individuals
SERUM URIC ACID
SEX HIGH LOW
MALE 38 32
FEMALE 19 11
P VALUE - 0.402
ODDS RATIO - 0.688
NON SIGNIFICANT
CHI SQUARE TEST
Table 18. Correlation   between  uric  acid  and  sex.
Chart  15. Correlation  between  uric  acid  and  sex.
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MEAN   URIC ACID   VS  GENDER
This  shows  that  mean  serum  uric  acid  in   male  is  7.13 mg/dl
and  female  is  7.09 mg/dl  and  there  is  no  significance statiscally.
SERUM URIC ACID
SEX MEAN SD
MALE 7.13 1.58
FEMALE 7.09 1.61
P VALUE - 0.900
NON SIGNIFICANT
UNPAIRED T TEST
Table  19. Mean  uric  acid  versus sex.
Chart  16.  Mean  uric  acid  versus  sex.
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SMOKING  AND  URIC ACID
This  table  correlates smoking  and  uric  acid  levels  in  study  group
SERUM URIC ACID
SMOKER HIGH LOW
YES 30 24
NO 27 19
P VALUE - 0.752
ODDS RATIO - 0.880
NON SIGNIFICANT
CHI SQUARE TEST
Table 20.  Correlation  between   uric  acid  and  smoking
Chart 17.  Correlation  between  uric  acid  and  smoking.
30
24
27
19
0
5
10
15
20
25
30
35
HIGH LOW
SERUM URIC ACID VS SMOKING
YES NO
87
SMOKING  AND   MEAN URIC  ACID
The  mean  serum  uric  acid  in smokers is  7.15 mg/dl and  non  smokers
is  7.08 mg/dl   and  it   is  not  statiscally  significant.
SERUM URIC ACID
SMOKING MEAN SD
PRESENT 7.15 1.63
ABSENT 7.08 1.54
P VALUE - 0.811
NON SIGNIFICANT
UNPAIRED T TEST
Table  21. Mean  uric  acid  versus   smoking.
Chart 18. Mean  uric  acid   versus  smoking.
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URIC ACID  AND  DIABETES  MELLITUS
This  table  shows  the  correlation  between  diabetes mellitus  and
uric  acid  by  chi square test. P  value  is  0.882  and  is  not  statiscally
significant.
SERUM URIC ACID
DIABETES MELLITUS HIGH LOW
PRESENT 22 16
ABSENT 35 27
P VALUE - 0.882
ODDS RATIO - 1.06
NON SIGNIFICANT
CHI SQUARE TEST
Table  22. Correlation  between  diabetes  mellitus  and  uric  acid.
Chart  19. Correlation  between diabetes mellitus and  uric  acid.
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MEAN  URIC   ACID  AND  DIABETES
Mean serum  uric  acid in  patients  with  diabetes  is  7.02 mg/dl  and  not
having  diabetes  is  7. 18 mg/dl . There is  no  significance  statiscally.
SERUM URIC ACID
DIABETES MELLITUS MEAN SD
PRESENT 7.02 1.67
ABSENT 7.18 1.54
P VALUE - 0.623
NON SIGNIFICANT
UNPAIRED T TEST
Table  23.  Mean  uric  acid versus  diabetes .
Chart  20. Mean  uric acid   versus  diabetes.
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HYPERTENSION  AND  URIC  ACID
In  hypertensive  patients  21  had  high  uric  acid  levels  and  18  had
low  levels. In  patients  without  hypertension  36  had  high  and  25  had
low uric  acid  levels.
SERUM URIC ACID
HYPERTENSION HIGH LOW
PRESENT 21 18
ABSENT 36 25
P VALUE - 0.610
ODDS RATIO - 0.810
NON SIGNIFICANT
CHI SQUARE TEST
Table  24  Correlation  between   hypertension  and  uric  acid.
Chart  21. Correlation  between  hypertension  and  uric  acid.
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HYPERTENSION  VERSUS  MEAN  URIC  ACID
Mean  uric  acid  among  hypertensive  patients  was  6.99 mg/dl. In
patients  without  hypertension  the   mean  uric  acid  was  7.2 mg/dl.
SERUM URIC ACID
HYPERTENSION MEAN SD
PRESENT 6.99 1.42
ABSENT 7.2 1.68
P VALUE - 0.518
NON SIGNIFICANT
UNPAIRED T TEST
Table  25.  Mean  uric  acid versus  hypertension.
Chart  22.  Mean  uric  acid  versus  hypertension
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URIC  ACID AND  NYHA  CLASS
This  shows  uric  acid  levels were  significantly  high  in  NYHA  class
III and  IV.
SERUM URIC ACID
NYHA CLASS HIGH LOW
I 4 3
II 12 18
III 21 16
IV 20 6
P VALUE - 0.05
SIGNIFICANT
KRUSKAL WALLIS TEST
Table  26. Correlation  between  NYHA  class  and  uric  acid.
Chart 23. Correlation between NYHA  class  and uric  acid.
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MEAN URIC ACID  VERSUS  NYHA  CLASS
This  table  shows  statiscally  significant  correlation  between  serum
uric  acid  levels  and  NYHA  class  among  study  group.
SERUM URIC ACID
NYHA MEAN S.D
I 6.21 1.2
II 6.52 1.3
III 7.38 1.6
IV 7.55 1.7
P VALUE - 0.042
SIGNIFICANT
ANOVA
Table  27.  mean  uric  acid  versus  NYHA  class
Chart 24.  Mean  uric  acid  versus  NYHA  class.
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EJECTION  FRACTION  AND  URIC  ACID
This  table  shows  that there  is  statiscally  significant   negative
correlation   between  ejection  fraction  and  uric  acid  levels.
SERUM URIC ACID
EJECTION FRACTION HIGH LOW
< 40% 42 19
> 40% 15 24
P VALUE - 0.003
ODDS RATIO - 3.53
SIGNIFICANT
CHI SQUARE TEST
Table  28. Correlation between  ejection  fraction  and  uric  acid
Chart  25. Correlation  between  ejection  fraction and  uric  acid.
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EJECTION   FRACTION  AND  MEAN  URIC  ACID
This  table  shows  mean   uric  acid  in  patients  with  low  EF  was
7.43mg/dl   and this  was  significantly  high.
SERUM URIC ACID
EJECTION FRACTION MEAN SD
< 40% 7.43 1.42
> 40% 6.64 1.71
P VALUE - 0.014
SIGNIFICANT
UNPAIRED T TEST
Table  29.  Mean    uric   acid   versus  ejection  fraction.
Chart 26. Mean  uric  acid  versus  ejection fraction
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AGE   VERSUS PROGNOSIS
There  was  significant  correlation  found. With  increase  in  age  the
mortality   was  high.
PROGNOSIS
AGE( IN YEARS) DIED ALIVE
<40 0 12
41-50 0 31
51-60 3 21
61-70 7 15
>70 6 5
P VALUE - 0.001
SIGNIFICANT
KRUSKAL WALLIS TEST
Table 30.  Age versus  prognosis.
Chart  27.  Age  versus  prognosis.
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MEAN  AGE VERSUS  PROGNOSIS
AGE
PROGNOSIS MEAN SD
DEAD 68.81 9.9
ALIVE 51.9 11.2
P VALUE - 0.001
SIGNIFICANT
UNPAIRED T TEST
Table  31. Mean  age  versus  prognosis.
Chart  28.  Mean  age versus  prognosis
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GENDER  VERSUS  PROGNOSIS
There  was  no significant  correlation  between  sex  of  the  individual
and  prognosis.
PROGNOSIS
SEX DIED ALIVE
MALE 9 61
FEMALE 7 23
P VALUE - 0.190
ODDS RATIO - 0.405
NON SIGNIFICANT
CHI SQUARE TEST
Table  32. sex  versus   prognosis.
Chart  29 . Sex versus  prognosis .
9
61
7
23
DIED ALIVE
SEX VS PROGNOSIS
MALE FEMALE
99
SMOKING  VERSUS  PROGNOSIS
This shows smoking  did not  affect the  mortality  significantly.
PROGNOSIS
SMOKER DEAD ALIVE
YES 8 46
NO 8 38
P VALUE - 0.726
ODDS RATIO - 0.826
NON SIGNIFICANT
CHI SQUARE TEST
Table  33. Smoking  versus  prognosis
Chart 30. Smoking   versus  prognosis.
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DIABETES  MELLITUS  VERSUS  PROGNOSIS
The  correlation  between  Diabetes  and  prognosis  of  patients  was  not
significant.
PROGNOSIS
DIABETES MELLITUS DEAD ALIVE
PRESENT 7 31
ABSENT 9 53
P VALUE - 0.605
ODDS RATIO - 1.33
NON SIGNIFICANT
CHI SQUARE TEST
Table  34. Diabetes  mellitus  versus  prognosis
Chart 31.   Diabetes  mellitus  versus   prognosis.
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HYPERENSION  VERSUS  PROGNOSIS
PROGNOSIS
HYPERTENSION HIGH LOW
PRESENT 6 33
ABSENT 10 51
P VALUE - 0.893
ODDS RATIO - 0.927
NON SIGNIFICANT
CHI SQUARE TEST
Table  35. Hypertension  versus  prognosis.
Chart 32.Hypertension  versus  prognosis .
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PROGNOSIS  VERSUS  NYHA  CLASS
This  table  shows  that  mortality  was high in  NYHA  class  III and  IV.
PROGNOSIS
NYHA CLASS DEAD ALIVE
ONE 0 7
TWO 0 30
THREE 3 34
FOUR 13 13
P VALUE - 0.001
SIGNIFICANT
KRUSKAL WALLIS TEST
Table  36.   NYHA  class  versus prognosis .
Chart  33.  NYHA  class  versus  prognosis.
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PROGNOSIS VERSUS NO  OF  ADMISSIONS
NO OF ADMISSIONS
PROGNOSIS MEAN SD
DEAD 1.88 0.8
ALIVE 1.62 0.84
P VALUE - 0.268
NON SIGNIFICANT
UNPAIRED T TEST
Table  37. Prognosis  versus   number  of  admissions.
Chart  34. Prognosis versus  No  of  admissions .
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PROGNOSIS  VERSUS  DURATION  OF  DISEASE
DURATION OF DISEASE
PROGNOSIS MEAN SD
DEAD 3.31 2.3
ALIVE 2.39 1.6
P VALUE - 0.063
NON SIGNIFICANT
UNPAIRED T TEST
Table  38.Duration  of  disease  versus  prognosis.
Chart 35. Duration  of  disease  versus  prognosis.
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EJECTION  FRACTION  VERSUS  PROGNOSIS
This  shows  mortality was  high  in  patients  with  low  ejection
fraction
PROGNOSIS
EJECTION FRACTION DEAD ALIVE
< 40% 16 45
> 40% 0 39
P VALUE - 0.001
ODDS RATIO - 6.53
SIGNIFICANT
CHI SQUARE TEST
Table  39. Prognosis versus  ejection  fraction
Chart  36. Prognosis  versus  ejection  fraction.
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MEAN  EJECTION FRACTION  AND  PROGNOSIS
This  shows  that  the  mean  ejection  fraction  in  patients  who   died
was  30.5 %.
EJECTION FRACTION
PROGNOSIS MEAN SD
DEAD 30.5 1.4
ALIVE 41.5 5.3
P VALUE - 0.001
SIGNIFICANT
UNPAIRED T TEST
Table  40.  Mean  EF  versus  prognosis.
Chart  37. Mean  EF  versus  prognosis.
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PROGNOSIS  VERSUS  SERUM   URIC  ACID
PROGNOSIS
SERUM URIC ACID DEAD ALIVE
> 6.8 13 44
< 6.8 3 40
P VALUE - 0.03
ODDS RATIO - 4.75
SIGNIFICANT
CHI SQUARE TEST
Table  41.  Correlation  between  uric  acid  and  prognosis
Chart  38. Correlation  between   uric  acid  and  prognosis
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MEAN  URIC  ACID  VERSUS  PROGNOSIS
The  mean  uric  acid level  in patients  who  died  was  significantly
elevated 8.21 mg/dl  as  compared  to  7.02 mg/dl  in  patients  who
survived  and was  statiscally  significant.
MEAN URIC ACID
PROGNOSIS MEAN SD
DEAD 8.21 1.32
ALIVE 7.02 1.61
P VALUE - 0.034
SIGNIFICANT
UNPAIRED T TEST
Table 42.Mean  uric  acid  and  prognosis.
Chart 39.  Mean  uric  acid  versus  prognosis.
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REGRESSION ANALYSIS
REGRESSION ANALYSIS
FACTORS P VALUE EXP(B) – ODDS RATIO
EJECTION FRACTION 0.015 6.2
NYHA CLASS 0.024 10.612
HYPRTENSION 0.739 0.744
DIABETES MELLITUS 0.680 0.666
SMOKING 0.657 1.937
SEX 0.518 0.349
AGE 0.014 2.962
URIC ACID 0.039 2.350
Table 43. Regression  analysis.
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DISCUSSION
In  my  study, patients  with  heart  failure  with  EF  <55%  were
taken  and  the  association  between  uric  acid  and  clinical  symptoms,
signs  and  various   risk   factors   was   analysed   and  observed  over  a
period  of  one  year. The  role  of  hyperuricemia  in the  outcome  of
heart  failure  patients  was  also  assessed. There  are   previous  studies
that uncovered  the association  of  serum  uric  acid  levels  and  the
development  of  heart  failure  in  population  of  patients  with  stable
coronary  heart  disease. Even  after  accounting  of multiple
confounding  factors  the  association  was found  to  be   significant.
Mazza  et al  found  that  the  relative  risk  of  coronary  heart  disease
death  in  elderly  individuals  with  diabetes  was  elevated in  patients
with  highest  and  lowest  levels of  uric  acid .Chang  fu  kuo et al in
their  study  proved  a  definite  evidence  that  describes  the  association
of  high   uric  acid  levels  and  mortality, which  was  previously
thought   to  be  controversial. In  my  study  it  was  found  that  there
was  a  significant  correlation  between  age  and  uric  acid with  a  p
value  of  0.002  which   was  statiscally  significant. With  increase  in
age  of  the  patients  the  level  of  uric  acid  in  serum  was  found  to  be
increased.
On  the other hand, a  significant  negative  correlation was  present
between  ejection  fraction  and  serum  uric  acid  levels. In  my  study
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hyperuricemia  (uric  acid  level > 6.8 mg /dl)  was  found  in  38 % of
patients  and  62%  of  patients  had  serum  uric  acid  < 6.8 mg/dl.
Serum  uric  acid  levels  and  its  correlation  with  sex  of  the
individuals  revealed  no  significance. Smoking  also  did  not  affect  the
uric  acid  levels  significantly. Uric  acid  levels  were  assessed  between
diabetic  and  patients  with  no  Diabetes  Mellitus  in  my  study.
Totally 38%  of  patients  had  diabetes  out  of  which  22  had  high  uric
acid  levels. 62%  patients  had  no  diabetes, among  them  35  patients
had  high uric  acid  levels. There was  no  statiscally  significant
correlation  between  diabetes  and  serum   uric  acid  levels  and  the  p
value  was  0.882. In  this  study, 39%  of  patients  were  hypertensive
and  61%  had  no  hypertension. It   was  found that   difference between
the mean  uric  acid  levels  in  both  groups  was  not  significant.
In  Apolipoprotein  mortality  risk   study  (AMORIS), moderate
levels  of  serum  uric  acid  were  linked  with  increased  incidence  of
acute  myocardial infarction, stroke  and HF  in  middle  age  subjects
without  CAD. AMORIS  study  implies  that   the  association  between
uric  acid  and  heart  failure  was  not  solely   mediated  by  myocardial
infarction,  but  other  mediators  present  in  CAD  may  be  involved .
Further  mechanisms  by   which  UA  could  be  associated   with  heart
failure  in  these   persons   includes  an  increased oxidative  burden,
increased  endothelial  dysfunction, a proinflammatory  state,  and
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subclinical atherosclerosis. Suggested variables  were  MI  size  and
effect  on  left  ventricular  function . In  my  study   patients  were
categorised  into  four  groups  based  on  New  York  Heart  Association
Classification(NYHA). Study  exposed  that  there  was  significantly
high  serum  uric  acid  levels  in  NYHA  class III  and  IV  patients. The
mean  serum  uric  acid  in   NYHA  class III and  IV  patients  was  7.38
mg/dl  and  7.55 mg/dl  respectively. In  this  study  38%  of  the
individuals  had  an  ejection  fraction   of  < 40%. The low  ejection
fraction  had  significant  negative  correlation  with   high  uric  acid
levels. The  p  value  obtained  by  chi  square  test   was  0.003. The
mean  uric  acid  in  patients  with  low  ejection  fraction  was  7.43
mg/dl.
In  total  number  of  patients, 16  patients  died  during  the  period
of  study. In patients with  hyperuricemia  the  prognosis  was  worse
with  rise  in  mortality  rates. The  mean  uric  acid  level in  patients
who  died  was 8.21 mg/dl  as  compared  to  7.02 mg/dl  in  patients  who
survived. The  p  value  was    0.034  and  was  significant. Several
studies  have  shown  an  association  between  hyperuricemia  in
congestive  heart  failure   and  morbidity  and   mortality. Data  from
Beta  Blocker  Evaluation  of  Survival  Trial6 took   a  different
approach   assuming  that  hyperuricemia  without  chronic  renal  failure
is  primarily  due  to  increased  production  of   UA  from  the  failing
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heart. The  conclusion  in  that  study  was   hyperuricemia  was
associated  with  poor  outcomes in  heart  failure  without  renal  failure.
The  correlation  between  low  EF  and  prognosis  was  statiscally
significant  with  p  value  of  0.001. The  mean  EF  in  patients  who
died   was  30.5%.  The  study  exposed  a  significant  increase  in
mortality  with  rise  in  age  of  the   patient. In  NYHA  class  III  and
IV  patients  the  death  of  patients  was  high  compared  to  class  I and
II.  This  was found  to  be  significant  with  a  P  value  of  0.001.
Regression analysis  was  also  performed  in  my  study  which  showed
significant  p  values  for  age, uric  acid, ejection  fraction  and  NYHA
class.
The  study  uncovered  that   sex, smoking,  Diabetes   mellitus and
Hypertension  did  not  affect  the  prognosis  of  heart  failure  patients
significantly. Gotsman  et  al7 found  in heart  failure  register  based
study   that  treatment  with  allopurinol   in  CHF  improved  survival
rates significantly. Another   retrospective  study examined  the  effect  of
allopurinol  on  mortality   and  hospilization  in  heart  failure  patients. It
was  found  that  high  dose  allopurinol (300 mg/ day) ,  a  xanthine
oxidase  inhibitor  was   associated  with  an  decrease  in  all   cause
mortality( p value - 0.05).
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CONCLUSION
In  my  study  hyperuricemia  was  observed  in  38%  of  heart
failure  patients with   EF <55%.  It  was  observed  that  NYHA  class  III
and  IV  patients  had  increased  uric  acid  levels. There   was
significant  negative  correlation  between  low  ejection  fraction  and
uric  acid. Hyperuricemia  was  associated  with  increased  mortality
rates.  This  clearly  establishes  the  role  of serum  uric  acid  levels  as  a
prognostic  marker  in  heart  failure  patients. Regardless  of  whether
uric  acid  levels  are  ready  for  clinical  use, either  as  prognostic
marker or  diagnostic marker  to  find  out the  morbidity, complications
and  subsequent  mortality in  heart  failure  patients, with  EF  < 55%
and  specifically  for  NYHA  III  and  IV   heart  failure  with  EF < 40%,
the  therapeutic  intervention  with  uric  acid  reducers, xanthine  oxidase
inhibitors  for  the  above  ailment  should  be  further   explored  with
large  multicentric, cross  sectional, double  blind  control   prospective
study. As   this  pathway  can  be  used   as  a  novel  therapeutic   target,
further  prospective  studies  are  needed  to  validate  that  routine
measurements  of  uric  acid   and  the  reduction  of  uric  acid  levels  in
this  group of   heart  failure   patients  alters  the morbidity and  mortality
rates.
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This  particular  study  is  a  single  centric  prospective  study
done  in a  limited  number of  patients to  validate  the  already  available
study  reports  saying,  uric  acid   can  be  used  as  a prognostic  marker
in  heart  failure.
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ANNEXURE 1
CASE PROFOMA
NAME
AGE / SEX                                                                      ADDRESS
OCCUPATION                                                               OP NO
HISTORY OF PRESENTING ILLNESS
PAST HISTORY
PERSONAL HISTORY
VITALS
GENERAL EXAMINATION
SYSTEMIC EXAMINATION
INVESTIGATIONS:
Blood sugar, blood  urea, serum  creatinine, serum  uric  acid
ECHO
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ANNEXURE -2
CONSENT FORM
Yourself Mr./Mrs./Ms………………………………..  are being asked to
be a participant in the research study titled  “Uric acid as a prognostic
marker in heart failure ”in CMC Hospital, Coimbatore, conducted by
DR D KAVI POORNIMA, Post Graduate Student, Department of
General Medicine, Coimbatore Medical College. You are eligible after
looking into the inclusion criteria. You can ask any question you may
have before agreeing to participate.
Research Being Done
Uric acid as a prognostic marker in heart failure
Purpose of Research
To identify  the  role of  uric  acid as  a  prognostic  marker in heart
failure
Decline from Participation
You  have  the  option to decline from  participation in the study existing
protocol for your condition.
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Privacy and Confidentiality
Privacy of individuals will be respected and any information about you or
provided by you during the study will be kept strictly confidential.
Authorization to publish Results
Results of the study may be published for scientific purposes and/or
presented to scientific groups, however you will not be identified.
Statement of Consent
I volunteer and consent to participate in this study. I have read the
consent or it has been read to me. The study has been fully explained to
me, and I may ask questions at any time.
------------------------------- -------------------------------
Signature /Left thumb impression                       Date
(volunteer)
-------------------------------- --------------------------------
Signature of witness                                               Date
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ஒ த ப வ
ெபய :
வய :
பாலின :
கவ :
ேகாைவ அர ம வ க ம வமைனய
ம வ ftp g{h]zpkh.J தைலைமய நைடெப இ த
ஆ வ ச மத ட கல ெகா ள ச மதி கிேற .
இ த ஆ வ எ ைன ப றி வவர கைள பா கா ட இ த
ஆ வ ெவளயட ஆ ேசபைண இ ைல எ ெத வ
ெகா கிேற .எ த ேநர தி ஆ வ இ எ த ேநர தி
வல கி ெகா உ ைம உ எ அறிேவ .
இட :
ேததி:
ைகெகயா ப /ேரைக
128
KEY TO MASTER CHART
DM - Diabetes Mellitus
SHT - Systemic Hypertension
EF - Ejection Fraction
NYHA - New York Heart Association
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ANNEXURE - 3
MASTER CHART
Name Age Sex Smoking
Crepitations
and pedal
edema
DM SHT NYHACLASS EF
Uric
acid
No of
admissions
Duration
of
disease
Result
Duraisamy 58 male no yes yes yes 1 >40 <6.8 1 4 discharged
Moudieen 48 male yes no yes no 2 >40 <6.8 2 2 discharged
Suseela 52 female no yes yes yes 4 <40 >6.8 2 4 discharged
Nataraj 60 male yes yes no yes 3 <40 >6.8 3 1 discharged
Mohammed ismail 45 male no no no no 3 >40 <6.8 4 1 discharged
Kamalam 68 female no yes yes yes 1 <40 >6.8 3 6 discharged
Janaki 72 female no yes no no 4 <40 >6.8 1 1 discharged
Shanmugam 38 male yes no no yes 3 >40 <6.8 2 2 discharged
Nayagam 48 female no no yes yes 2 <40 <6.8 2 2 discharged
Krishnan 75 male yes yes no no 3 <40 >6.8 1 7 died
Ramasamy 61 male yes no no no 2 >40 >6.8 2 3 discharged
Rangan 49 male no no no yes 3 <40 >6.8 3 2 discharged
Krishnasamy 58 male yes no no no 2 <40 >6.8 2 8 died
Selvi 54 female no yes yes no 4 <40 >6.8 3 5 discharged
Joseph 36 male no no no yes 3 <40 >6.8 1 2 discharged
Kannan 49 male no yes no yes 4 >40 <6.8 1 4 discharged
Manokar 44 male yes no yes no 1 >40 >6.8 3 2 discharged
Balan 27 male yes yes no no 3 <40 <6.8 1 1 discharged
Padmanaban 66 66 male yes yes no no 3 <40 >6.8 1 1 died
Parthiban 52 male yes yes yes yes 4 <40 >6.8 1 3 died
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Kannagi 48 female ni no yes no 2 <40 >6.8 2 2 discharged
Nagaraj 59 male no yes no yes 3 <40 >6.8 3 2 discharged
Kamatchi 48 female no no yes yes 2 >40 <6.8 2 3 discharged
Rajammal 52 female no yes no no 3 <40 <6.8 2 6 died
Rangasamy 75 male yes yes no no 4 <40 >6.8 4 2 discharged
Rejendran 46 male no no yes no 3 >40 >6.8 1 5 discharged
Mahendran 47 male yes no no yes 3 >40 <6.8 3 3 discharged
Mahalingam 57 male yes no no no 2 <40 <6.8 2 6 discharged
Periasamy 65 male yes yes no yes 3 >40 >6.8 2 9 discharged
Suppan 80 male yes yes yes no 4 <40 >6.8 1 2 died
Subbathal 47 female no no yes no 1 >40 >6.8 2 3 discharged
Radhakrishnan 58 male yes no no no 2 >40 <6.8 1 1 discharged
Baskaran 62 male yes yes no yes 3 >40 <6.8 3 4 discharged
Natarajan 38 male yes no no yes 1 >40 <6.8 4 3 discharged
Gunasekaran 54 male no yes yes no 3 <40 <6.8 2 6 discharged
Gnanasekaran 45 male yes no yes no 2 <40 >6.8 1 3 discharged
Prakasam 49 male yes no no no 1 >40 <6.8 1 1 discharged
Pandurangan 68 male yes yes no no 4 <40 >6.8 3 2 died
Lakshmi 55 female no no no yes 2 <40 <6.8 2 5 discharged
Murugan 46 male yes yes no yes 2 <40 >6.8 3 2 discharged
Karuppusamy 67 male yes yes yes yes 4 <40 >6.8 3 4 died
Andal 70 female no yes no yes 3 >40 >6.8 1 1 discharged
Agilandeshwari 56 female no no yes no 4 <40 <6.8 2 7 discharged
Kuppusamy 43 male yes no no no 2 <40 >6.8 1 1 discharged
Ramalakshmi 42 female no no no yes 1 >40 >6.8 1 1 discharged
Balamurugan 39 male yes no yes no 3 <40 <6.8 1 1 discharged
Muruganandan 34 male no yes yes no 2 >40 <6.8 2 2 discharged
Raman 46 male yes no no no 3 <40 >6.8 1 3 discharged
Rajesh 42 male yes no no no 2 >40 <6.8 1 2 discharged
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Suppi 78 female no yes no no 4 <40 >6.8 2 3 died
Kumarasamy 65 male yes yes yes yes 3 >40 <6.8 2 2 discharged
Abdul ahmed 54 male yes no no no 2 <40 >6.8 1 3 discharged
Moideen 47 male yes yes no yes 3 <40 <6.8 1 2 discharged
Suresh 32 male yes no no no 2 >40 <6.8 1 3 discharged
Sekar 42 male no no no yes 2 >40 <6.8 1 2 discharged
Chandran 56 male yes no yes yes 2 <40 >6.8 2 3 discharged
Murugammal 81 female no yes no yes 3 <40 <6.8 2 1 died
Suppamal 69 female no no yes no 2 <40 >6.8 1 1 discharged
Pushpam 64 female no yes yes yes 4 <40 >6.8 2 3 died
Raja rajan 47 male yes no no yes 2 >40 <6.8 2 1 discharged
Murugesan 56 male yes no no no 3 <40 <6.8 1 4 discharged
Chellapan 84 male no yes no no 4 <40 >6.8 3 4 died
Ravi 42 male yes no yes no 2 >40 <6.8 2 2 discharged
Sankarasamy 38 male yes no no no 2 <40 <6.8 1 2 discharged
Chinnasamy 74 male yes no no yes 3 <40 <6.8 1 1 discharged
Senthil kumar 35 male yes no yes no 2 >40 <6.8 1 1 discharged
Sivakumar 45 male no no no no 2 >40 >6.8 1 1 discharged
Geetha 47 female no no yes yes 3 <40 >6.8 1 1 discharged
Parameshwaran 58 male yes yes no yes 4 >40 >6.8 2 5 discharged
Palaniappan 66 male no yes yes no 2 <40 >6.8 1 1 discharged
Kumaresan 57 male yes no no no 3 <40 >6.8 1 4 discharged
Mohanraj 43 male no no no no 2 >40 <6.8 1 1 discharged
Pushpalatha 68 female no yes yes yes 4 <40 <6.8 1 1 died
Kalavathy 55 female no no yes no 3 <4.8 >6.8 3 3 discharged
Shanthi 61 female no no no no 2 <40 >6.8 1 1 discharged
Kumar 58 male yes yes no no 3 <40 <6.8 1 1 discharged
Sivaraj 38 male yes yes no yes 3 >40 >6.8 1 1 discharged
Murali krishnan 48 male yes no yes no 3 <40 <6.8 1 1 discharged
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Manivannan 49 male yes no no no 2 >40 >6.8 2 1 discharged
Selvi 62 female no yes yes no 4 <40 >6.8 1 1 died
Hari 35 male no no no yes 2 <40 <6.8 1 1 discharged
Sudhakar 63 male no no no yes 3 <40 >6.8 2 5 discharged
Palanisamy 58 male yes no no no 3 <40 >6.8 1 1 discharged
Ramkumar 54 male yes yes yes no 3 >40 >6.8 1 1 discharged
Karthi 47 male yes no no no 4 <40 >6.8 1 3 discharged
Velusamy 78 male yes no no no 3 <40 >6.8 3 6 died
Gandhi 64 male yes yes yes yes 4 <40 >6.8 1 1 discharged
Usha 65 female no no yes yes 3 >40 >6.8 3 4 discharged
Bharathi 53 female no no no no 2 >40 <6.8 1 1 discharged
Saravanan 47 male yes no no no 3 >40 >6.8 1 1 discharged
Rajamani 68 female no yes yes yes 4 <40 <6.8 2 1 died
Jaganathan 65 male yes no no yes 3 <40 >6.8 1 1 discharged
Ramani 67 female no yes yes no 4 >40 >6.8 1 1 discharged
Kannaian 72 male yes yes no no 4 <40 >6.8 1 1 discharged
Kowsalya 43 female no no yes no 3 >40 <6.8 1 1 discharged
Velmurugan 56 male yes no no no 2 >40 <6.8 1 1 discharged
Anushya 63 female no yes no no 3 <40 >6.8 1 2 discharged
Babu 32 male yes no no no 4 <40 <6.8 1 1 discharged
Rani 43 female no no yes no 3 > 40 <6.8 1 3 discharged
Thulasi 78 female no yes no no 4 <40 >6.8 1 4 discharged
